COPD Insights for Primary Care: 5 New Studies

Reduced exacerbations, improved lung function, increased QoL, and less use of systemic corticosteroids underscore dupilumab's effects against type 2 inflammation.

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

As flu season approaches this year, experts stress that it's not just about influenza anymore; they discuss testing, antiviral treatment, and management of coinfection.

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

The FDA approved Abrysvo for use in pregnant individuals to prevent LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age.

Approximately 80% of infants hospitalized with an RSV-related illness during the 2022 seasonal peak did not have underlying medical conditions, according to new study.